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Abstract: Background: The benefits of antiretroviral therapy for HIV-infected subjects
have been limited by an increased risk of metabolic and cardiovascular diseases. The
objective of this study was to assess the effects of a low dose of marine omega-3 fatty
acids on inflammatory marker concentrations in HIV-infected subjects under antiretroviral
therapy (ART). Methods: This was a randomized, parallel, placebo-controlled trial that
investigated the effects of 3 g fish oil/day (540 mg of eicosapentaenoic acid—EPA plus
360 mg of docosahexaenoic acid—DHA) or 3 g soy oil/day (placebo) for 24 weeks in
83 male and non-pregnant female HIV-infected adults on ART. Results: There were no
differences between groups for the measures at baseline. Multilevel analyses revealed no
statistically significant relationship between the longitudinal changes in high sensitivity-C
reactive protein (hs-CRP) (Wald Chi2 = 0.17, p = 0.918), fibrinogen (Wald Chi2 = 3.82,
p = 0.148), and factor VIII (Wald Chi2 = 5.25, p = 0.073) with fish oil. No significant
changes in interleukin-6 (IL6), interleukin-1 beta (IL1-beta) and tumor necrosis factor-alpha
(TNF-alpha) serum concentrations were observed with fish oil supplements for 12 weeks.
Conclusions: Compared to placebo, a low dose of 900 mg omega-3 fatty acids (EPA plus
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DHA) in fish oil capsules did not change hs-CRP, fibrinogen, factor VIII, IL6, IL1-beta and
TNF-alpha serum concentrations in HIV-infected subjects on ART. Further investigations
should consider the assessment of more sensitive inflammatory markers or higher doses
to evaluate the effects of marine omega-3 fatty acids in this population. Registered at the
Nederlands Trial Register, Identifier no. NTR1798.
Keywords: HIV infection; AIDS; metabolic syndrome; inflammation; C reactive protein;
fibrinogen; factor VIII; interleukin 6; interleukin 1-beta; tumor necrosis factor-alpha
1. Introduction
The benefits of antiretroviral therapy (ART) on morbidity and mortality of HIV-infected subjects
have been limited by the increased risk of the metabolic syndrome [1] and cardiovascular diseases [2].
Although the basic mechanisms of these alterations are still not completely elucidated, they are probably
secondary to a synergistic effect between HIV infection, certain antiretroviral drugs, genetic, and
environmental factors [3].
There is increasing evidence supporting the role of inflammation in the metabolic syndrome and
cardiovascular (CV) diseases and some biomarkers of chronic mild inflammation are emerging as novel
CV risk factors [4–7]. Concomitantly, clinical trials have assessed the effects of marine omega-3
fatty acids as anti-inflammatory agents in subjects with the metabolic syndrome and cardiovascular
diseases [8]. We have found only one publication that has investigated the impact of omega-3 fatty
acids on the inflammatory profile of HIV-subjects on ART [9]. Thus, the aim of this paper is to
answer the following question: Can a low dose of marine omega-3 fatty acids reduce or prevent the
increases in concentrations of C reactive protein (hs-CRP), fibrinogen, factor VIII, interleukin-6 (IL-6),
interleukin-beta (IL-beta), and tumor necrosis factor-alpha (TNF-alpha) in HIV-infected subjects on
antiretroviral treatment? The rationale for choosing these inflammatory markers was related to their
association with cardiovascular disease (hs-CRP, fibrinogen, VIII factor) and with components of the
metabolic syndrome (IL-6, IL-beta, TNF-alpha).
2. Materials and Methods
This was a randomized, parallel, placebo-controlled trial registered at the Nederlands Trial Register,
Identifier no. NTR1798. The study was developed at an HIV/AIDS Care Centre in São Paulo city, Brazil,
affiliated to the Medical School, University of São Paulo.
The sample size was calculated to detect a mean difference of 0.40 mg/L in hs-CRP concentrations
between groups (power: 95%, alpha: 5%), and adjusted for an estimated follow-up loss rate of 25%,
resulting in 120 subjects („60 per group).
From January to October 2009, 768 subjects’ medical records were evaluated for eligibility. The
inclusion criteria were: Men or non-pregnant women, between 19 and 64 years old, on at least three
months of stable ART, blood triglycerides >100 mg/dL (1.13 mmoL/L), LDL-Cholesterol (LDL-C)
concentrations <160 mg/dL (4.14 mmoL/L), fasting glucose <126 mg/dL (7.0 mmoL/L), without
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symptoms of any comorbidity, and not currently using any nutritional supplement, anticoagulant,
hypoglycaemic, or lipid lowering drugs. From May 2009 to October 2010, 215 subjects were invited
to participate in the trial by phone or during their routine health care at the Centre by one of the
authors, JMO, and 120 subjects gave their consent. The study was approved by the Ethics in Research
Committees of the Public Health School and Medical School Hospital, University of Sao Paulo, Brazil.
The subjects were divided into two groups using a randomized number table generated in Excelr.
The intervention group received 3 g fish oil/day (n = 62, 3 capsules weighting 1 g each, total 540 mg of
eicosapentaenoic acid—EPA plus 360 mg of docosahexaenoic acid—DHA) or 3 g of soy oil/day (n = 58,
3 placebo capsules with 1 g each) for 24 weeks. The supplements were provided by Relthyr Pharmacy
Company (Indaiatuba, Sao Paulo, Brazil). The fish oil and placebo capsules were almost identical with
a slight difference in color. Although the study was designed to be double-masked, during the protocol
some subjects detected a fishy taste so we decided not to consider this a masked trial. Fish oil capsule
compliance and potential side effects were monitored during follow up. The subjects received three
bottles of supplement at baseline and at 12 weeks, and were asked to return these, empty or not, at the
12 weeks and 24 weeks visit, respectively. The adherence was calculated by the ratio of the numbers of
capsules provided to those returned.
A questionnaire was administered by JMO and other field staff to obtain socioeconomic, demographic
and health information. Weight and height (in duplicate) were obtained with a portable Tanitar
balance and a CMS Weighing Equipmentr anthropometer, as weight in kg/(height in meters)2. Body
circumferences (waist, hip and neck) were measured (in duplicate) with a TBWr non-elastic metric tape.
Serum hs-CRP, fibrinogen, and factor VIII were determined at the Central Laboratory of the Medical
School Hospital, University of Sao Paulo. Subjects’ blood samples were collected at baseline, and at the
12 week and 24 week visit, after 12 h of fasting. Serum hs-CRP was analyzed by immunoturbidimetry
(CardioPhaser hs-CRP, Siemens, Berlin, Germany). Fibrinogen was determined by modified Clauss
method and factor VIII was estimated based on the activated partial thromboplastin time (APTT) (BCS
Systemr XP, Siemens, Berlin, Germany). The lymphocyte T CD4+ and CD8+ were analyzed by flow
cytometry (FACSCaliburr, BD Biosciences, San Jose, CA, USA) and HIV viral load was determined by
directed quantification of HIV-1 RNA in plasma (Bayer Systemr 340—bDNA Analyzer).
Serum IL-6, IL-1beta and TNF-alpha were evaluated by ELISA (enzyme-linked immunosorbent assay
with kits from R&D Systems, MN, USA, Quantikine) at the Immunology Laboratory, Adolfo Lutz
Institute. Serum hs-CRP was determined by immunoturbidimetry (CardioPhaser hs-CRP, Siemens),
lymphocytes T CD4+ and CD8+ were analyzed by flow cytometry (FACSCaliburr, BD Biosciences) at
the Central Laboratory of the Medical School Hospital, University of Sao Paulo. For these inflammatory
markers, measures were obtained only at the baseline and at the 12th week visit.
Between the baseline and 12 weeks, 26 subjects dropped out, and between 12 and 24 weeks, a further
12. During the analysis, data from 11 subjects who started lipid-lowering medications and those with
hs-CRP >10 mg/L were excluded, because of the possibility of an intercurrent infection. Thus, our final
sample was 83 subjects with at least two measurements: Baseline and 12th week visit. Among these
83 subjects, we had three measurements: Baseline, 12th week visit, and 24th week visit for 71 subjects.
Further design details are in Oliveira et al. [10], where a flow diagram of patients recruited and the
reasons for dropping out can be found.
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The primary outcomes were not normally distributed; thus, the data are expressed as median and
inter-quartile range. The non-parametric Mann-Whitney test was used for inter-group comparisons at
baseline. The same test was applied to assess changes in serum IL-6, IL-1beta and TNF-alpha after 12
weeks of intervention. For serum hs-CRP, fibrinogen and VIII factor, multilevel analyses with random
effects were carried out to assess the longitudinal fish oil effects. The differences were considered
statistically significant based on a p value of <0.05 regarding Mann-Whitney Tests and multilevel
analyses. Data were analyzed with the software Stata 9 (Stata Corporation, College Station, TX, USA).
3. Results
Subject characteristics are described in Table 1. Eighty three men and women with a mean of age
43.0 ˘ 6.8 years (range 26–61) were included. The mean CD4+ cell count was 604 ˘ 315 cells/mm3,
and was comparable between groups. The majority of subjects were male, single/divorced/widowed,
had normal BMI and were on protease inhibitors. Adherence to supplements was 85.1% (7.7%) and
83.7% (13.5%) in the fish oil and placebo groups, respectively. Some subjects from the fish oil group
experienced transient episodes of diarrhoea (n = 4), abdominal pain (n = 2), loss of appetite (n = 1),
heartburn (n = 2), and headache (n = 3). Only two subjects from the placebo group experienced transient
episodes of diarrhoea (n = 1), and heartburn (n = 1). All these side effects developed early during the
study and did not result in patients stopping the supplements. No effects of the fish oil were noted on
CD4+ count, CD4+/CD8+ ratio or viral load.
There were no statistically significant differences between groups at baseline for primary outcomes
(Tables 2 and 3). No significant relationships were observed between the administration of fish oil
supplements and changes in concentrations of inflammatory markers (Tables 3 and 4).
Table 1. Characteristics of the subjects.
Characteristics/Groups Fish Oil Placebo Total
N (%) 43 (51.8%) 40 (48.2%) 83 (100%)
Age, mean (SD) 43.1 (7.4) 42.8 (6.3) 43.0 (6.8)
Gender, n (%)
Male 33 (76.7%) 31 (77.5%) 64 (77.1%)
Female 10 (23.3%) 9 (22.5%) 19 (22.9%)
Marital status
Married/stable relationship 19 (44.2%) 18 (45.0%) 37 (44.6%)
Single/divorced/widowed 24 (55.8%) 22 (55.5%) 46 (55.4%)
Socio-economic factors, mean (SD)
Per capita income/month 2.5 (1.7) 3.3 (3.0) 2.9 (2.4)
Years of study 13.2 (4.3) 12.3 (3.8) 12.7 (4.1)
Life style characteristics, n (%)
Smoking 14 (32.6%) 21 (52.5%) 35 (42.2%)
Alcohol intake 29 (67.4%) 26 (65.0%) 55 (66%)
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Table 1. Cont.
Nutritional status, mean (SD)
BMI 24.8 (3.6) 23.2 (3.8) 24.0 (3.8)
Waist circumference (cm) 89.2 (10.2) 85.0 (10.8) 87.2 (10.6)
Waist/hip ratio 0.92 (0.08) 0.90 (0.08) 0.91 (0.08)
Neck circumference (cm) 38.4 (3.6) 36.8 ( 3.5) 37.7 (3.6)
HIV/Aids parameters, mean (SD)
CD4+ cell count (cells/mm3) # 591.8 (259.6) 616.2 (366.9) 603.8 (315.4)
CD4+/CD8+ ratio 0.93 (0.69) 0.74 (0.41) 0.84 (0.58)
HIV viral load ## 40.3 (182.5) 65.8 (244.7) 53.0 (214.8)
Years of infection 10.3 (5.7) 10.9 (5.0) 10.6 (5.4)
Years of ART 8.3 (4.1) 9.2 (3.5) 8.7 (3.9)
Current ART, n (%)
2 NRTI + 1 NNRTI 20 (46.5%) 15 (37.5%) 35 (42.2%)
2 NRTI + 1 PI 6 (14.0%) 2 (5.0%) 8 (9.6%)
2 NRTI + 2 PI 13 (30.2%) 14 (35.0%) 27 (32.5%)
Other combinations 4 (9.3%) 9 (22.5%) 13 (15.7%)
Use of PI 22 (51.2%) 25 (62.5%) 47 (56.6%)
Use of NNRTI 21 (48.8%) 16 (40.0%) 37 (44.5%)
Supplement compliance, mean (SD) ** 85.1% (7.7%) 83.7% (13.5%) 84.4% (11.0%)
* In Brazilian Minimum Wages—BMW (one BMW = 306 US dollar); # two missing values; ## one outlier
value excluded; SD: standard deviation; ART: antiretroviral therapy; NRTI: nucleoside reverse transcriptase
inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; ** 10 missing values.
Table 2. Primary endpoints—C Reactive Protein, Fibrinogen, Factor VIII.
Fish Oil Placebo
N Median (IQR) N Median (IQR)
High sensitivity C-reactive protein (mg/L)
Baseline * 43 2.34 (0.74–3.75) 40 1.68 (0.76–3.23)
12th week 42 1.93 (0.79–3.15) 36 1.40 (0.87–3.13)
24th week 31 2.36 (0.65–3.52) 35 2.10 (0.94–3.40)
Fibrinogen (mg/dL)
Baseline ** 43 266 (236–364) 39 323 (260–415)
12th week 42 275 (234–349) 35 320 (251–405)
24th week 31 262 (233–346) 34 306 (245–388)
VIII factor (%)
Baseline *** 43 92 (65–110) 38 83 (69–113)
12th week 42 83 (61–106) 33 78 (51–97)
24th week 30 96 (87–117) 34 98 (81–111)
Inter-group comparisons at baseline: * p = 0.548, ** p = 0.070, *** p = 0.898.
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Table 3. Primary endpoints—Interleukin 6, Interleukin1-beta, Tumor necrosis factor-alpha.
Placebo Fish Oil
N Median (IQR) N Median (IQR)
Interleukin 6 (pg/mL)
Baseline * 36 1.72 (1.21, 3.01) 42 1.93 (0.02, 3.43)
12th week 36 1.31 (1.00, 2.00) 42 1.49 (0.74, 2.48)
Change # 36 ´0.32 (´0.89, 0.48) 42 ´0.36 (´1.13, 0.52)
Interleukin 1—Beta (pg/mL)
Baseline ** 36 0.23 (0.05–0.52) 42 0.15 (0.02, 0.47)
12th week 36 0.25 (0.13–0.56) 42 0.17 (0.01, 0.43)
Change ## 36 0.00 (´0.19–0.18) 42 0.00 (´0.22, 0.24)
Tumor necrosis factor—Alpha (pg/mL)
Baseline *** 36 1.05 (0.74, 1.98) 42 0.96 (0.58, 1.94)
12th week 36 0.95 (0.68, 1.47) 42 0.78 (0.55, 1.13)
Change ### 36 ´0.06 (´0.92, 0.28) 42 ´0.17 (´0.71, 0.11)
Inter-group comparisons at baseline: * p = 0.936, ** p = 0.615, *** p = 0.464; Inter-group changes comparisons
after 12 weeks: # p = 0.976, ## p = 0.884, ### p = 0.508; IQR: interquartile range.
Table 4. Primary endpoints—Multilevel models.
Coefficient SD z p 95% Confidence Interval
hs-CRP
Fish oil 0.070 0.186 0.38 0.705 ´0.293 to 0.434
Time 0.009 0.049 0.17 0.861 ´0.088 to 0.105
Constant 0.425 0.164 2.59 0.010 ´0.104 to 0.747
Wald Chi2 = 0.17, p = 0.918
Fibrinogen
Fish oil ´0.099 0.052 ´1.92 0.055 ´0.200 to 0.002
Time ´0.004 0.012 ´0.39 0.699 ´0.029 to 0.020
Constant 4.767 0.444 129.78 0.000 5.680 to 5.854
Wald Chi2 = 3.82, p = 0.148
VIII factor
Fish oil 0.007 0.058 0.12 0.902 ´0.106 to 0.120
Time 0.061 0.027 2.29 0.022 ´0.009 to 0.114
Constant 4.328 0.067 64.40 0.000 ´4.196 to 4.460
Wald Chi2 = 5.25, p = 0.073
hs-CRP: high sensitivity C reactive protein.
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4. Discussion
In the present study, a low dose of marine omega-3 fatty acids (540 mg EPA and 360 mg DHA)
for 24 weeks did not change hs-CRP, fibrinogen, and factor VIII in treated HIV-infected subjects. As
far as we know, this is the first study that has assessed the influence of marine omega-3 fatty acids on
fibrinogen and factor VIII. Only one previous study has investigated the effects of these fatty acids on
hs-CRP concentrations in a population undergoing treatment with ART [9]. Our results are consistent
with previous studies in non HIV-infected populations [8,11,12].
There are four possible explanations for the absence of effects. First, the duration of supplementation
with omega-3 fatty acids might have been insufficient to reverse the disturbances produced by long
term exposure to HIV infection (10.6 ˘ 5.4 years) and ART (8.7 ˘ 3.9 years), and the high prevalence
of smoking (42.2%) and alcohol consumption (66%). Second, the use of inflammatory markers to
evaluate sub-clinical inflammation can be confounded by the susceptibility to opportunistic infection
in this group. Third, a low dose of marine omega-3 fatty acids might have been insufficient to
reduce inflammatory markers concentration in this population. Fourth, it is possible that the reported
anti-inflammatory effects of marine omega-3 fatty acids are related to other physiological pathways
rather than through a pathway involving CRP, fibrinogen, and factor VIII.
There are some limitations on this research that might have influenced our results, including the losses
to follow up. Additionally, recruitment was limited by the fact that 72.0% of the 768 subjects whose
records were scanned for eligibility, but were not on stable ART, and/or had high triglycerides, LDL-C
concentrations, fasting glucose, and/or were taking anticoagulant, hypoglycaemic, lipid lowering drugs.
Balk et al. [12] reviewed the effects of omega-3 fatty acids on several cardiovascular risk factors and
intermediate markers in healthy adults or those at increased risk of cardiovascular disease and did not
find a consistent effect on levels of fibrinogen and factor VIII. Madsen et al. [8] did not detect significant
reductions in hs-CRP concentrations in subjects with previous myocardial infarction after 12 weeks of
supplementation with 5.2 g of omega-3 fatty acids. Thusgaard et al. [9] investigated the impact of 4 g of
omega-3-acid ethyl esters (1520 mg DHA plus 1840 mg EPA) for 12 weeks on the inflammatory profile
of HIV subjects treated with ART and described no changes in hs-CRP. Similarly, Metkus et al. [13]
assessed the effect of 3.6 g omega-3-acid ethyl esters for eight weeks on inflammatory markers of HIV
subjects and did not observe significant reduction in hs-CRP, making it unlikely that our findings were
the consequence of an inadequate dose of the fatty acids. Moreover, our exclusion of data from subjects
with high levels of CRP would have minimized the influence of intercurrent infection.
The mechanisms whereby marine omega-3 fatty acids might modulate inflammation include acting
through a reduction and increase, respectively, of inflammatory and anti-inflammatory mediators.
According to James et al. [14] doses of 2400 mg to 4500 mg of EPA + DHA can reduce monocyte
synthesis of TNF-alpha and IL1-beta in healthy subjects and in those with rheumatoid arthritis. The
ingestion of fish oil results in an elevated concentration of EPA and DHA in inflammatory cells.
Consequently, there is a decrease in production of some eicosanoids such as prostaglandins E2 (PGE2),
which induces the production of IL-6; and leucotriene B4 (LTB4), a chemotactic agent involved in
the stimulation of macrophage production of IL-6, IL-1beta and TNF-alpha [14]. EPA is a substrate
of cyclooxygenase and lipoxygenase enzymes and is converted to anti-inflammatory eicosanoids such
as those of the PG3 and LT5 series [15]. Moreover, EPA and DHA are enzymatically converted into
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resolvins and protectins, which mediate resolution of acute phase reactions [16]. These novels mediators
are involved in blocking T-cell migration and promoting apoptosis, as well as in blocking neutrophil
migration, infiltration and recruitment [17]. In the trial by Thusgaard et al. [9] a significant rise in LTB5,
an anti-inflammatory factor, was noted with supplementation of omega-3 fatty acids. Thus, further
investigations should consider the assessment of more sensitive inflammatory markers to evaluate the
effects of marine omega-3 fatty acids in HIV-infected subjects on ART.
5. Conclusions
In conclusion, a low dose of marine omega-3 fatty acids administered to HIV/Aids subjects on ART
over 12 and 24 weeks did not influence levels of inflammatory markers.
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